Sugi Predict

Sugi Predict / Compounds / SCHEMBL18151008

SCHEMBL18151008

SCHEMBL18151008

NS(=O)(=O)c1ccc(-c2ccc3nc4n(c3c2)C(c2ccccc2)CC4)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 15/20 0.43
▸ CA1 P00915 14/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CFTR P13569 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ GOPC Q9HD26 1/20 0.42
▸ CA9 Q16790 6/20 0.41
▸ CA12 O43570 5/20 0.41
▸ PTGS2 P35354 2/20 0.41
▸ ATM Q13315 1/20 0.39
▸ RIPK1 Q13546 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18150867 0.89 RIPK1 (0.46) ALDH1A1PTGS2RIPK1
SCHEMBL18150952 0.87 RIPK1 (0.48) RIPK1
SCHEMBL18151648 0.86 RIPK1 (0.40) ALDH1A1ATMRIPK1
SCHEMBL18151020 0.86 RIPK1 (0.39) L3MBTL1ALDH1A1PTGS2RIPK1
SCHEMBL18159818 0.83 KMT2A (0.52) L3MBTL1KDM4EALDH1A1GAAMAPT
SCHEMBL18151053 0.83 RIPK1 (0.45) ATMRIPK1
SCHEMBL18151730 0.83 CHEK2 (0.41) RIPK1
SCHEMBL18151397 0.81 PIK3CB (0.44) ALDH1A1PTGS2ATMRIPK1
SCHEMBL18151489 0.80 ATM (0.41) ATM
SCHEMBL18150808 0.80 RIPK1 (0.40) KDM4EALDH1A1RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP claimed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US claimed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO claimed
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins AVILAR THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 — — US disclosed
EP-4493221-A2 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2025-01-22 — — EP disclosed
CN-119212727-A Targeted bifunctional degradants 耶鲁大学 2024-12-27 — — CN disclosed
WO-2024182772-A2 MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023178199-A2 TARGETED BIFUNCTIONAL DEGRADERS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, MDM2 CA2 2814/4885CA1 1671/4885L3MBTL1 1396/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B CA2 2924/4885CA1 3404/4885L3MBTL1 1884/4885
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 CA2 4310/4885CA1 4287/4885L3MBTL1 4129/4885
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins IGF2R, M6PR, MSR1 CA2 2683/4885CA1 4085/4885L3MBTL1 3196/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 CA2 4310/4885CA1 4287/4885L3MBTL1 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.